Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.55 |
| ▸ | JAK1 | P23458 | 14/20 | 0.41 |
| ▸ | TYK2 | P29597 | 13/20 | 0.41 |
| ▸ | JAK2 | O60674 | 11/20 | 0.41 |
| ▸ | JAK3 | P52333 | 8/20 | 0.41 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.37 |
| ▸ | CDK9 | P50750 | 2/20 | 0.37 |
| ▸ | CDK4 | P11802 | 1/20 | 0.37 |
| ▸ | CCND1 | P24385 | 1/20 | 0.37 |
| ▸ | CCND3 | P30281 | 1/20 | 0.37 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.37 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
| ▸ | IKBKB | O14920 | 1/20 | 0.33 |
| ▸ | CHUK | O15111 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17113385 | 0.85 | SYK (0.75) | SYKJAK1TYK2JAK2JAK3 | |
| SCHEMBL17129840 | 0.83 | SYK (0.62) | SYKJAK1TYK2JAK2JAK3 | |
| SCHEMBL17113602 | 0.82 | SYK (0.70) | SYKJAK1TYK2JAK2JAK3 | |
| SCHEMBL17113444 | 0.82 | SYK (0.70) | SYKJAK1TYK2JAK2JAK3 | |
| SCHEMBL17113599 | 0.82 | SYK (0.54) | SYKJAK1TYK2JAK2JAK3 | |
| SCHEMBL17113328 | 0.78 | SYK (0.54) | SYKJAK1TYK2JAK2JAK3 | |
| SCHEMBL18627953 | 0.76 | SYK (0.61) | SYKJAK1TYK2JAK2JAK3 | |
| SCHEMBL17113586 | 0.75 | SYK (0.58) | SYK | |
| SCHEMBL17113590 | 0.75 | SYK (0.69) | SYKJAK1TYK2JAK2JAK3 | |
| SCHEMBL17113521 | 0.75 | SYK (0.69) | SYKJAK1TYK2JAK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3122744-B1 | DIAZASPIROALKANEONE-SUBSTITUTED OXAZOLE DERIVATIVES AS SPLEEN TYROSINE KINASE INHIBITORS | AB SCIENCE (FR) | 2018-11-07 | — | — | EP | claimed |
| US-10053455-B2 | Diazaspiroalkaneone-substituted oxazole derivatives as spleen tyrosine kinase inhibitors | AB SCIENCE (FR) | 2018-08-21 | — | — | US | claimed |
| US-20180179195-A1 | DIAZASPIROALKANEONE-SUBSTITUTED OXAZOLE DERIVATIVES AS SPLEEN TYROSINE KINASE INHIBITORS | AB SCIENCE (FR) | 2018-06-28 | — | — | US | claimed |
| EP-3122744-A1 | DIAZASPIROALKANEONE-SUBSTITUTED OXAZOLE DERIVATIVES AS SPLEEN TYROSINE KINASE INHIBITORS | AB Science (FR) | 2017-02-01 | — | — | EP | claimed |
| WO-2015144614-A1 | DIAZASPIROALKANEONE-SUBSTITUTED OXAZOLE DERIVATIVES AS SPLEEN TYROSINE KINASE INHIBITORS | AB SCIENCE (FR) | 2015-10-01 | — | — | WO | claimed |
| EP-3122744-B1 | DIAZASPIROALKANEONE-SUBSTITUTED OXAZOLE DERIVATIVES AS SPLEEN TYROSINE KINASE INHIBITORS | AB SCIENCE (FR) | 2018-11-07 | — | — | EP | disclosed |
| US-10053455-B2 | Diazaspiroalkaneone-substituted oxazole derivatives as spleen tyrosine kinase inhibitors | AB SCIENCE (FR) | 2018-08-21 | — | — | US | disclosed |
| US-20180179195-A1 | DIAZASPIROALKANEONE-SUBSTITUTED OXAZOLE DERIVATIVES AS SPLEEN TYROSINE KINASE INHIBITORS | AB SCIENCE (FR) | 2018-06-28 | — | — | US | disclosed |
| US-20180179195-A1 | DIAZASPIROALKANEONE-SUBSTITUTED OXAZOLE DERIVATIVES AS SPLEEN TYROSINE KINASE INHIBITORS | AB SCIENCE (FR) | 2018-06-28 | — | — | US | disclosed |
| US-20180179195-A1 | DIAZASPIROALKANEONE-SUBSTITUTED OXAZOLE DERIVATIVES AS SPLEEN TYROSINE KINASE INHIBITORS | AB SCIENCE (FR) | 2018-06-28 | — | — | US | disclosed |
| WO-2015144614-A1 | DIAZASPIROALKANEONE-SUBSTITUTED OXAZOLE DERIVATIVES AS SPLEEN TYROSINE KINASE INHIBITORS | AB SCIENCE (FR) | 2015-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10053455-B2 | Diazaspiroalkaneone-substituted oxazole derivatives as spleen tyrosine kinase inhibitors | SYK, ZAP70, LCK | SYK 1/4885JAK1 86/4885TYK2 36/4885 |
| US-20180179195-A1 | DIAZASPIROALKANEONE-SUBSTITUTED OXAZOLE DERIVATIVES AS SPLEEN TYROSINE KINASE INHIBITORS | SYK, ZAP70, LCK | SYK 1/4885JAK1 86/4885TYK2 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.